KPV
Anti-Inflammatory Tripeptide
KPV is a C-terminal tripeptide of alpha-MSH (melanocyte-stimulating hormone), retaining the anti-inflammatory core of its parent molecule in a small, stable, highly bioavailable form. It has emerged as one of the most researched peptides for gut inflammation — particularly in IBD models — and is now being investigated across skin and wound healing applications.
At a Glance
Alpha-MSH is a well-studied anti-inflammatory peptide, but its 13-amino-acid size limits stability and bioavailability. KPV distills the active anti-inflammatory C-terminal sequence into just three amino acids — small enough to survive oral administration in research models and reach inflamed tissue.
Its primary mechanism involves direct interaction with the melanocortin receptor (MC1R) and inhibition of NF-κB — the master regulator of inflammatory gene expression. This makes KPV a targeted anti-inflammatory rather than a broad immunosuppressant.
Research has expanded beyond gut inflammation into skin — topical KPV has shown efficacy in atopic dermatitis and psoriasis models, adding a surface application dimension that complements its oral and injectable research uses.
NF-κB Inhibition
Directly inhibits NF-κB nuclear translocation — reducing expression of pro-inflammatory cytokines (IL-1β, IL-6, TNF-α) without broad immunosuppression.
MC1R Agonism
Binds melanocortin 1 receptor on immune cells to downregulate inflammatory signaling — the same mechanism as its parent peptide alpha-MSH.
Gut Barrier Protection
Supports intestinal epithelial integrity and reduces mucosal inflammation in IBD models — studied in both Crohn's and ulcerative colitis contexts.
Wound & Skin Repair
Topical application studied in atopic dermatitis and psoriasis — anti-inflammatory mechanism translates directly to skin inflammation models.
- Inflammatory bowel disease (IBD) — Crohn's and ulcerative colitis preclinical models
- Gut barrier integrity — prevention and repair of intestinal permeability
- Wound healing — anti-inflammatory phase acceleration
- Atopic dermatitis — topical application studies
- Psoriasis models — skin inflammation reduction
- Systemic anti-inflammatory without immunosuppression — key differentiator from corticosteroids
- Combination protocols with BPC-157 for comprehensive gut and repair coverage
| Aspect | KPV | BPC-157 | GHK-Cu |
|---|---|---|---|
| Primary Mechanism | NF-κB inhibition, MC1R | Angiogenesis, cytoprotection | Collagen synthesis, gene expression |
| Best Application | Gut inflammation, skin | Tendon, gut, CNS | Skin, wound, anti-aging |
| Oral Bioavailability | Confirmed preclinical | Confirmed preclinical | Limited — topical preferred |
| Anti-Inflammatory | Primary mechanism | Secondary mechanism | Secondary mechanism |
| Best Stacked With | BPC-157, GHK-Cu | TB-500, KPV | BPC-157, KPV |
Oral bioavailability confirmed — stable in gastric acid and reaches intestinal tissue intact
Targeted mechanism — NF-κB inhibition without broad immunosuppression or steroid effects
Multiple administration routes — oral, SC, and topical all studied
Evidence base still developing — strong preclinical data but limited human clinical trials versus established anti-inflammatory agents
This overview is strictly educational and based on publicly available scientific literature as of 2026. It does not constitute medical advice. All Helixera Labs products are for laboratory research use only. Not for human or veterinary use. · Helixera Labs LLC © 2026